IconOVir Bio is developing oncolytic virus therapy to target and destroy cancer cells while sparing healthy tissue. This approach aims to improve treatment outcomes for patients with various types of cancer by harnessing the body's immune response.
Funding
$97.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often harm healthy tissues alongside cancerous cells, leading to significant side effects and limiting the effectiveness of therapy. Traditional approaches may not fully eradicate cancer, resulting in recurrence and reduced quality of life for patients.
Solution
IconOVir Bio is developing oncolytic virus therapy designed to selectively target and destroy cancer cells while preserving healthy tissue. This therapeutic approach leverages the body's own immune system to combat cancer, aiming to improve treatment outcomes and minimize adverse effects. By specifically attacking cancer cells, the therapy seeks to reduce the likelihood of recurrence and enhance the overall well-being of patients undergoing treatment. The company's mission is to cure cancer and restore life to every patient.
Target Audience
The primary target audience includes patients with various types of cancer and the healthcare providers who treat them, including oncologists and hospitals.
Features
- Oncolytic virus therapy selectively targets and destroys cancer cells.
- Spares healthy tissue, reducing side effects compared to traditional cancer treatments.
- Harnesses the body's immune response to fight cancer.